Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

被引：0

作者：

C K Lee

R J Simes

C Brown

S Lord

U Wagner

M Plante

I Vergote

C Pisano

G Parma

A Burges

H Bourgeois

T Högberg

J Bentley

L Angleitner-Boubenizek

A Ferrero

B Richter

H Hirte

V Gebski

J Pfisterer

E Pujade-Lauraine

M Friedlander

机构：

[1] NHMRC Clinical Trials Centre,Department of Gynecology

[2] University of Sydney,Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology

[3] Gynecologic Endocrinology and Oncology,Division of Medical Oncology B

[4] University Hospital of Gießen and Marburg,Department of Gynecology and Obstetrics

[5] CHUQ- Hotel Dieu de Quebec,Department of Onco

[6] University Hospital Leuven,Hematology

[7] National Cancer Institute,Department of Gynaecologic Oncology

[8] Medical Gynecologic Oncology Unit,Academic Division of Gynecologic Oncology

[9] European Institute of Oncology,Department of Gynecology and Obstetrics

[10] Klinikum University of Munic,Department of Gynecology

[11] Campus Großhadern,undefined

[12] Centre Jean Bernard – SARL SORECOH,undefined

[13] Linkjoping University Hospital,undefined

[14] Dalhousie University,undefined

[15] 5820 University Avenue,undefined

[16] BHS Linz,undefined

[17] Seilerstätte 4,undefined

[18] Mauriziano Hospital,undefined

[19] University of Dresden,undefined

[20] Juravinski Cancer Centre at Hamilton Health Sciences,undefined

[21] Staedt. Klinikum Solingen,undefined

[22] Université Paris Descartes,undefined

[23] AP-HP,undefined

[24] Hôpitaux Universitaires Paris Centre,undefined

[25] Site Hôtel-Dieu,undefined

[26] Oncologie,undefined

[27] Prince of Wales Hospital,undefined

[28] Institute of Oncology,undefined

来源：

British Journal of Cancer | 2011年 / 105卷

关键词：

nomogram; recurrent ovarian cancer; prognosis; platinum sensitivity; progression-free survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1144 / 1150

页数：6

共 261 条

[1] Bishara S(2008)Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynecol Reprod Biol 138 71-75
[2] Griffin M(1989)Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 650-653
[3] Cargill A(2002)Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens J Clin Oncol 20 1232-1237
[4] Bali A(2009)Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment Cancer Immunol Immunother 58 15-23
[5] Gore ME(1972)Regression models and life-tables J R Stat Soc B 34 187-220
[6] Kaye SB(2003)A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 1320-1329
[7] Shepherd JH(1997)Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 963-968
[8] Van Trappen PO(2008)Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer Gynecol Oncol 109 187-193
[9] Blackledge G(2007)Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann Oncol 18 263-268
[10] Lawton F(2004)Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 1-8

← 1 2 3 4 5 6 7 8 9 10 →